Ciba Seeks FDA Clarification On Possible Triclosan “Data Gaps”
This article was originally published in The Tan Sheet
Executive Summary
Ciba Specialty Chemicals is seeking a meeting with FDA staff to discuss "outstanding issues" relating to triclosan safety, the company says in a recent letter to the agency
You may also be interested in...
FDA Seeks Data On Triclosan, Considers OTC Acne Monograph Inclusion
FDA is issuing a call-for-data for information on the safety and effectiveness of triclosan when used as an anti-acne ingredient
Triclosan Antigingivitis/Antiplaque Monograph Status Sought By Ciba
Ciba Specialty Chemicals requests that FDA include triclosan in its upcoming OTC monograph for antigingivitis/antiplaque oral care products in a recently-filed application
Triclosan Efficacy Studies Support “Significant” Antimicrobial Effect – Ciba
New in vitro and in vivo studies on triclosan "substantially augment" the evidence supporting Category I status for the antimicrobial ingredient, Ciba Specialty Chemicals maintains in a Feb. 11 citizen petition to FDA